

[REDACTED]

---

**From:** [REDACTED] <[REDACTED]@abbott.com>  
**Sent:** 24 January 2023 19:09  
**To:** Bellahn, Inga  
**Cc:** [REDACTED] [REDACTED] ADC Complaints QA  
**Subject:** RE: MHRA FU letter  
**Attachments:** MHRA FU letter 24Jan2023.pdf

Hi Inga,

[REDACTED]

Also, to discuss point 3 on page one of the letter, would you have availability for a 1 hour call tomorrow (25<sup>th</sup> January) between 2pm – 5pm?

Look forward to your feedback.

Kind regards,  
[REDACTED]



[REDACTED]  
EMEAP

Abbott Diabetes Care Ltd  
Range Road  
Witney  
Oxfordshire  
OX29 0YL

O: [REDACTED]  
M: [REDACTED] [@abbott.com](mailto:[REDACTED]@abbott.com)

---

This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.

---

**From:** [REDACTED]  
**Sent:** 24 January 2023 17:57  
**To:** Bellahn, Inga <Inga.Bellahn@mhra.gov.uk>  
**Cc:** [REDACTED] [REDACTED] <[REDACTED]@abbott.com>; ADC Complaints QA <ADCComplaintsQA@abbott.com>  
**Subject:** RE: MHRA FU letter

Dear Inga,

Thank you for sending this follow-up letter. I acknowledge receipt and can confirm that our team is in the process of reviewing the requests. Thank you also for offering to be the contact point if we needed additional clarifications.

We will be back in touch as soon as our review is complete.

Kind regards,  
[REDACTED]



[REDACTED]  
EMEAP

Abbott Diabetes Care Ltd  
Range Road  
Witney

O: [REDACTED]  
M: [REDACTED] [@abbott.com](mailto:[REDACTED]@abbott.com)

This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.

---

**From:** Bellahn, Inga <[Inga.Bellahn@mhra.gov.uk](mailto:Inga.Bellahn@mhra.gov.uk)>  
**Sent:** 24 January 2023 14:55  
**To:** [REDACTED] <[REDACTED]@abbott.com>  
**Cc:** [REDACTED] <[REDACTED]@abbott.com>  
**Subject:** MHRA FU letter  
**Importance:** High

**EXTERNAL EMAIL: Only click links or open attachments if you recognize the sender and know the content is safe**

Dear [REDACTED], dear [REDACTED]

Following the information provided during our meeting last week, please find points for follow up in the attached letter.

I would be grateful if you could acknowledge receipt. Please don't hesitate contacting me should anything need further clarification.

Kind regards,  
Inga

**Inga Bellahn, PhD**  
Head of Metabolic Disorders and Renal Systems  
Benefit/Risk Evaluation II, Safety and Surveillance Group  
Medicines and Healthcare Products Regulatory Agency  
10 South Colonnade, Canary Wharf, London, E14 4PU  
✉ [inga.bellahn@mhra.gov.uk](mailto:inga.bellahn@mhra.gov.uk)

Follow us on social media: <https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency#what-we-do>

**[Read our guidance on coronavirus \(COVID-19\)](#)**

DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click [DHTermsAndConditions](#)

---

**\*\* IMPORTANT NOTICE \*\***

Abbott Diabetes Care Ltd, Registered Number 2548046 England & Wales - Registered Office Range Road, Witney, Oxfordshire OX29 0YL. VAT Reg GB 537 1507 52. If you have received this email in error please contact the sender and remove the email from your system. This communication and any attachments contain information that

is confidential and may also be privileged. If you are not the intended recipient, note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful. Any views or opinions expressed are those of the originator and not necessarily those of Abbott Diabetes Care Ltd. Email communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, destroyed, arrive late or incomplete, or contain viruses. We do not accept liability for any such matters or their consequences. Anyone who communicates with us by email accepts the risks in doing so.